Targeting RNA‐binding Proteins for Cancer Therapy

Chengpiao Lu,Guoqiang Xu,Jingjing Ma

DOI: https://doi.org/10.1002/ctd2.232

2023-01-01

Clinical and Translational Discovery

Abstract:In this commentary, we briefly summarize the function of RNA-binding proteins (RBPs) and the major discovery for IGF2BP3 in the paper that will be published in Clin Transl Med. We also introduce the mechanism of how the E3 ligase Parkin mediates the ubiquitination and function of its new substrate IGF2BP3. Finally, we discuss the future perspectives on the strategies for the regulation of IGF2BP3 and other RBPs. RNA binding proteins (RBPs) interact with messenger RNA (mRNA) to regulate their stability, metabolism, localization, modification, splicing, and translation.1, 2 Dysregulation of RBPs is associated with cancer cell proliferation, metastasis, and sensitivity of tumour cells to chemotherapeutic drugs.3–5 Therefore, RBPs become appealing drug targets. RBPs could be regulated at different levels, including transcriptional, post-transcriptional, translational and post-translational levels, resulting in precise modulation of their expression and biological functions. Ubiquitination is a major post-translational modification (PTM) that determines protein fate and function. Specific E3 ligases and deubiquitinating enzymes (DUBs) could modulate the ubiquitination and degradation of RBPs under physiological or pathological conditions. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) affect several aspects of target RNAs and are involved in many physiological and pathological processes, including cancer development and progression.6 All three isoforms, IGF2BP1/2/3, belong to a conserved family of zipcode-binding proteins. They are composed of two RNA-recognition motifs (RRMs) in their N-termini and four K-homology (KH) RNA-binding domains in their C-termini (Figure 1A). IGF2BPs could be regulated by multiple enzymes including E3s and DUBs in the ubiquitin system (Figure 1B).7–15 In a paper recently published in Clin Transl Med, Sun et al.16 reported that IGF2BP3 was a new substrate of the Parkin E3 ligase in cervical cancer cells and tissues through proteomics and biochemical experiments. In vitro and in vivo experiments demonstrated that Parkin ubiquitinated IGF2BP3 at K213 and promoted its proteasomal degradation. IGF2BP3 K213R mutation inactivated the downstream PI3K and MAPK signalling pathways, attenuated the Parkin-mediated mitophagy, and abolished its oncogenic function (Figure 1C). This work discovered an important role of ubiquitination in the regulation of IGF2BP3 function in tumorigenesis and might lead to the discovery of new therapeutic approaches for the treatment of cervical cancer in the future. Ubiquitination plays diverse roles in regulating the functions of modified substrates, mainly depending on the type of ubiquitination, such as monoubiquitination and different types of linkage-specific polyubiquitination. Therefore, it is necessary to elucidate the underlying molecular mechanism and the resulting functions of the associated ubiquitination. In the paper published by Sun et al,16 bioinformatics analyses revealed that IGF2BP3 was significantly upregulated while Parkin was downregulated in human cervical cancer cell lines and tissues and their expression was potentially associated with the survival of cervical cancer patients. Their previous proteomics study discovered that IGF2BP3 might be a new substrate of Parkin.17 Biochemical experiments disclosed that Parkin overexpression downregulated while PARK2 (encodes Parkin) knockdown elevated IGF2BP3. Liver tissue from PARK2 knockout mice exhibited a higher IGF2BP3 level than wild-type mice. To further elucidate the regulatory mechanism, the authors validated their interaction and identified their interacting domains. Cell-line-based experiments and in vitro ubiquitination assay further revealed that Parkin enhanced the K48-linked polyubiquitin chains on IGF2BP3 whereas the activity-deficiency Parkin mutation reduced IGF2BP3 ubiquitination. Functionally, Parkin expression significantly reduced the binding of IGF2BP3 to its target genes including MYC, TK1, FSCN1 and MARCKSL1 and thus attenuated their expression. The proteomic analysis pinpointed K213 as a candidate ubiquitination site on IGF2BP3 and biochemical experiments further confirmed that Parkin could not degrade the IGF2BP3 K213R mutant, resulting in the increased stability. Their transcriptome sequencing identified 437 downregulated genes and 126 upregulated genes in IGF2BP3 K213R mutant-expressing cells. The downregulated genes were associated with cell proliferation, also including MYC, TK1, FSCN1 and MARCKSL1, which is consistent with the inhibition of IGF2BP3 function mediated by Parkin. Furthermore, IGF2BP3 K213R mutation attenuates its binding to the PARK2 gene, leading to decreased PARK2 mRNA stability and expression, increased mitochondrial proteins, reduced mitolysosomes, and inhibited mitophagy, suggesting that the cell growth inhibition by IGF2BP3 K213R mutation may be attributed to the decreased mitophagy. The xenograft tumour model demonstrated that IGF2BP3 K213R mutation significantly decreased the expression of Ki-67 and MYC, cell proliferation, and tumorigenesis in cervical cancer cells. Based on their study, they concluded that IGF2BP3 ubiquitination mediated by Parkin was indispensable for its oncogenic function and analysis of IGF2BP3 ubiquitination could be a good biomarker for cervical cancer. Lysine residues can be modified by many PTMs. Sun et al.16 discovered that Parkin mediated the ubiquitination of GF2BP3 at K213 and its oncogenic function. However, it is difficult to rule out the contribution of other PTMs. It is unknown whether acetylation, ubiquitin-like modification or other lysine modifications could potentially contribute to the biological functions of IGF2BP3 at K213. Although Sun et al.’s work demonstrated that Parkin regulated mitophagy and cell viability in cervical cancer cells by promoting the ubiquitination and degradation of IGF2BP3, two other isoforms IGF2BP1/2 were also the targets of Parkin.16 It is interesting to explore whether these two proteins participate in the regulation of Parkin-induced mitophagy or cancer cell growth. It is unclear whether and how other Parkin substrates contribute to the biological functions of Parkin in cervical cancer cells since many substrates have been identified for Parkin. Previous work has concluded that Parkin exerted the tumour-suppressive effect. However, this work demonstrated that Parkin ubiquitinated and degraded IGF2BP3 and the IGF2BP3 K213R mutant reduced the activation of the oncogenic PI3K/MAPK pathways. This function is different from other ubiquitin-mediated degradation of protein substrates. On the one hand, the data suggest that IGF2BP3 K213R mutation might execute the dominant negative effect or functions other than the reduction of ubiquitination. On the other hand, Parkin could mediate monoubiquitination and polyubiquitination of mitochondrial proteins with different chain linkages, such as K6-, K11-, K27-, K48- and K63-linked polyubiquitin chains. Different types of polyubiquitin chains most probably exhibit distinct biological functions. The formation of other types of ubiquitination on IGF2BP3 may occur proceeding to the formation of K48-linked polyubiquitin chains for proteasomal degradation. Further experiments are required to distinguish these hypotheses. Many studies suggest that RBPs could be therapeutic targets for cancer treatment.18, 19 However, RBPs were previously considered “undruggable” due to their flexible structures and lack of high-affinity binding pockets. Fortunately, there are several ways to modulate their protein level and thus biological functions. In the case of IGF2BP3, three different levels were discovered to modulate its expression (Figure 1D). First, IGF2BP3 mRNA expression could be regulated at the gene levels by epigenetic modification, transcriptional regulation of gene expression, fusion of the IGF2BP3 gene with other genes, and regulation of mRNA stability and expression by microRNAs. Second, IGF2BP3 could also be regulated at the post-translational level. Ubiquitination and phosphorylation modulate the IGF2BP3 stability and its binding to the downstream targeting mRNAs. Indeed, the proteomic study of the IGF2BP3 complex in Sun et al.’s work16 identified other E3 ligases including ARIH1, HECTD1, HUWE1, RNFs, TRIP12, TRIMs, UBRs, etc. Many of them exhibit diverse functions and are closely associated with cancer development.20–-23 Therefore, this work provides an excellent resource for future studies in the regulation of IGF2BP3. Third, IGF2BP3 protein activity could be inhibited by small molecules extracted from plants or synthesized chemically. The above strategies, such as small molecule inhibitors or genetic manipulation by siRNA oligonucleotides (Figure 2), also work for the regulation of RBPs other than IGF2BP3. Interestingly, molecular glue or proteolysis-targeting chimaeras (PROTACs) become compelling approaches to modulate previously thought “undruggable” targets such as RBPs (Figure 2). One of the recently discovered examples is to use of indisulam and its derivatives to degrade RBM39,24-26 which is highly expressed in several cancers, thus reducing the viability of cancer cells. The second example is to use PROTACs, which link the ligand of an E3 ligase (or its substrate receptor) with the ligand of protein of interest (POI, such as RBPs in this case), to induce the ubiquitination and degradation of RBPs. The third example in this scenario is to covalently fuse an RNA fragment to a peptide or small molecule, which functions as a ligand of an E3 ligase or its substrate receptors such as von Hippel-Lindau and cereblon, forming RNA-PROTAC.27, 28 Therefore, RBPs that interact with the specific RNA fragment could be ubiquitinated and degraded. It is compelling to further explore other possible approaches29 to manipulate RBPs for targeted cancer therapy. This work was supported by the National Natural Science Foundation of China (32171437), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (22KJB310017), Gusu Key Health Talent Program of Suzhou (GSWS2022122), a project funded by the Priority Academic Program Development (PAPD) of the Jiangsu Higher Education Institutions of China. The authors declare no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.